Salazar E

Language: Spanish
References: 12
Page: 202-206
PDF size: 54.19 Kb.

ABSTRACT

The pharmacological treatment of the angina pectoris syndromes consists of: a) anti-ischemic therapy to relieve the symptoms and improve the quality of life, b) treatment aimed at preventing myocardial infarction and death, and c) measures to modify or reduce the risk factors for coronary disease. Revascularization procedures, coronary artery bypass grafting, or percutaneous coronary interventions, are used to improve prognosis, relieve symptoms, prevent ischemic complications, and improve functional capacity. In patients with mild angina, medical therapy, percutaneous coronary interventions and coronary artery bypass surgery are all reasonable options. However, there are indications for pharmacological treatment in the great majority of patients with angina. After a revascularization procedure the patient should continue to receive antiplatelet agents and follow a program of coronary risk factors modification.

REFERENCES

1. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM et al: ACC/ AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33: 2092-2197.

2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al: ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines) Committee on Management of Patients With Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.

3. Yusuf S, Wiittes J, Friedman L: Overview of Results of Randomized Clinical Trials in Heart Disease. II Unstable Angina, Heart Failure, Primary Prevention With Aspirin, and Risk Factor Modification. JAMA 1988; 260: 2259-2263.

4. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW et al: Effect of coronary artery bypass graft surgery on survival: overview of 10 –years results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570.

5. The CASS investigators: Ten-Year Follow-up of Quality of Life in Patients Randomized to Receive Medical Therapy or Coronary Artery Bypass Graft Surgery. The Coronary Artery Surgery Study (CASS). Circulation 1990; 82: 1647-1658.

6. THE RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina:the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997; 350: 461-468.

7. Hueb WA, Bellotti G, Almeida de Oliveira S, Arie S, Piva de Albuquerque C, Jatene AD Pileggi F: The Medicine, Angioplasty or Surgery Study (MASS): A Prospective, Randomized Trial of Medical Therapy, Balloon Angioplasty or Bypass Surgery for Single Proximal Left Anterior Descending Artery Stenoses. J Am Coll Cardiol 1995; 26: 1600-1605.

8. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coranary revascularization. N Engl J Med 1997; 336: 1689-1696.

9. The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.

10. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

11. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol Reduction Yields Clinical Benefit. Impact of Statin Trials. Circulation 1998; 97: 946-952.

12. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.